Shattuck Labs Q4 2024 net loss $18.7M; advances SL-325 DR3 antibody to Phase 1

Shattuck Labs, Inc.

Cash and investments $73.0M as of Dec 31, 2024; expected to fund operations into 2027.
Net loss Q4 2024 $18.7M ($0.37/share) vs $17.7M ($0.41) Q4 2023; FY loss $75.4M vs $87.3M.
R&D expenses $15.4M Q4; full year $67.2M down from $74.3M due to termination of SL-172154 program.
SL-325 DR3 blocking antibody on track for IND filing in Q3 2025; Phase 1 enrollment expected complete Q2 2026.
Preclinical NHP data at ECCO showed favorable safety, full receptor occupancy, no DR3 agonism.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.